Use of GLP-1 receptor agonists — including drugs such as Wegovy, Ozempic, Mounjaro and Zepbound — continues to reshape treatment patterns for obesity, diabetes and beyond. Several March studies and surveys highlight how these medications are shifting patient behavior, influencing…
GLP-1s
A March analysis from KFF aims to shed light on CMS’ upcoming BALANCE model for GLP-1 coverage — highlighting financial requirements, operational mandates and unresolved policy questions — ahead of its 2027 launch. The model, announced in December, builds on the…
Cost is not the primary barrier keeping Americans from weight loss drugs, despite historically high list prices and inconsistent insurance coverage, according to a March 17 Axios-Ipsos poll. The finding is based on survey responses from a nationally representative sample…
Researchers at Washington University School of Medicine in St. Louis found stopping GLP-1 medications is linked to a 22% increase in heart attack, stroke and death after two years. The study, published March 18 in BMJ Medicine, follows more than…
The highest dose of Eli Lilly’s investigational drug, retatrutide, helped adults with Type 2 diabetes lower their A1Cs about 2% and shed an average 33.3 pounds, or 15.3% of their body weight, in a clinical trial. Retatrutide is a triple…
Advertisement
GLP-1 receptor agonists were associated with reduced risk of alcohol, cannabis, cocaine, nicotine and opioid use disorders, as well as other substance use disorders, suggesting potential prevention effects across a broad range of substances, according to a study published March…
Since late 2022, rising uptake of GLP-1 medications for obesity has coincided with a decline in bariatric surgeries, according to a growing body of research. A study published March 4 in JAMA Surgery found the swelling popularity of GLP-1 drugs…
Discontinuing GLP-1 treatment does not always cause significant weight gain, as many patients transition to other obesity or diabetes treatments, according to a Cleveland Clinic study published March 12 in Diabetes, Obesity and Metabolism. One year after discontinuation, 19.6% of…
Although one GLP-1 study made national headlines about the drug class’ potential use in addiction treatment, other research indicates GLP-1s could increase the risk of bone injuries and are less effective than other medications for chronic kidney disease. Here are…
Amazon Pharmacy has added Eli Lilly’s Zepbound KwikPen in the 2.5-mg starter dose for $299 per month through its cash-pay model. Zepbound is a multidose injectable medication approved for chronic weight management and, more recently, moderate-to-severe obstructive sleep apnea. With…